Dynavax Reports Preclinical Study Publication of TLR9 Agonist for Treatment of Lung Cancer

 Dynavax Reports Preclinical Study Publication of TLR9 Agonist for Treatment of Lung Cancer

Dynavax Reports Preclinical Study Publication of TLR9 Agonist for Treatment of Lung Cancer

Shots:
  •  Study involves assessing of inhaled TLR9 agonist with anti-PD-1 in mouse preclinical model, leading a long term survival in two different mouse lung tumour models 
  • Administration of SD-101 in lungs of mice with metastatic tumours results in ~90% reduction in tumour burden in lung and liver both enhancing survival time and survival rate of 90-100 days
  •  An unpublished P-1b study involving TLR9 agonist, DV281 for lung tumours and lung metastases has shown corresponding results in above models of inhaled DV281 being evaluated for advanced NSLC patients 

Click here to read full press release/ article | Ref: Dynavax | Image: Market Exclusive

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post